All News

James F. Howard, MD, discusses what he believes will be the next steps in treating myasthenia gravis.

Trauma after cancer is underdiagnosed and often persists into survivorship, with experts urging trauma-informed screening in oncology care.

As quarantined cruise passengers return home, experts explain Andes hantavirus symptoms, transmission risks, and prevention.

Community oncology practices face major infrastructure and reimbursement gaps when delivering bispecific antibodies.

New CMS Medicaid work requirements could increase employment but may also cause millions of adults to lose coverage by 2027.

Real-world data suggest nirogacestat boosts response in desmoid tumor vs standard-of-care treatment, but small cohorts leave key outcomes unanswered.

Medicare’s GLP-1 Bridge offers temporary coverage for obesity medication at $50/month, but patients face a 2027 cliff as BALANCE stalls.

Abortion costs and Medicaid coverage vary by state, creating financial barriers for patients seeking care after the Dobbs v Jackson decision.

Accountable care offers one of the most promising frameworks for stabilizing and expanding access, but only if policy is intentionally designed to support rural participation.

Girls and young women, as well as older teens, were more likely to report AI chatbot use for mental health advice, with Black youth more likely to engage monthly.

Data confirm the use of daratumumab, bortezomib, lenalidomide, and dexamethasone as the standard of care in newly diagnosed multiple myeloma.

Children aged 2 to 5 years with fall birthdays had higher flu vaccination rates and fewer diagnoses than those with summer birthdays.

FDA approves ensitrelvir for COVID-19 postexposure prophylaxis following phase 3 data showing efficacy against Omicron symptoms.

Asthma and Allergy Awareness Month shines light on the ways that asthma can affect long-term health.

Phase 3 trials show bepirovirsen delivers ~20% functional cure in chronic hepatitis B in just 24 weeks.

An entirely new approach to treating one of the most intractable cancers could turn it into a chronic disease.

Adding the anti-CD19 monoclonal antibody and lenalidomide to the classic combination drove superior PFS, with a positive trend in OS. Higher rates of adverse events offset the positive survival results in an area of great unmet need.

Older adults began to experience self-reported visual disability at a threshold of 1.60 logCS, which provides a benchmark for contrast sensitivity.

Pulmonary rehabilitation boosts respiratory strength, the 6-minute walking test, and quality of life in children despite unchanged spirometry.

Men with multiple sclerosis (MS) were more likely to lose income earlier in life compared with women with MS.

DELTA 2 data show topical delgocitinib for chronic hand eczema delivers minimal systemic absorption even under maximal-use conditions.

Teclistamab bispecific from Johnson & Johnson boosts early-line multiple myeloma outcomes, fueling safer outpatient therapy options.

Systematic review finds SGLT2 inhibitors and newer CKD drugs boost QALYs and often save costs by delaying dialysis and transplant.

New data showed durable hepatitis D virus RNA suppression through 96 weeks with tobevibart plus elebsiran, while higher BMI appeared to affect ALT normalization.

Reports highlight gaps in private equity oversight, MA vs FFS outcomes, cancer care access advances, climate health disparities, and uneven genomic testing.

New US chronic hand eczema guidance closes diagnostic gaps and spotlights emerging therapies like delgocitinib to cut itch, pain, and work disruption.

Two posters presented at EASL 2026 clarify where peginterferon alfa-2b fits in therapy for patients with chronic hepatitis B.

Heiner Wedemeyer, MD, offered an unflinching assessment of viral hepatitis medicine, celebrating landmark breakthroughs while issuing a clear warning that the field is failing the populations it set out to protect.